Division of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
Lung Cancer. 2010 Sep;69(3):315-8. doi: 10.1016/j.lungcan.2009.11.016. Epub 2010 Jan 13.
There has been no report about re-challenge chemotherapy (RC) consisting of the same regimen as first-line chemotherapy in non-small-cell lung cancer (NSCLC). The aim of this study was to evaluate the efficacy of RC as second-line chemotherapy in patients with relapsed NSCLC. We conducted a retrospective review of 28 consecutive NSCLC patients who were treated with RC and compared their clinical outcomes with those of 38 consecutive NSCLC patients who were treated with docetaxel (DOC) at our hospital between July 1992 and December 2003. The RC group consisted of 21 men and 7 women, with a median age of 62 years (range, 42-76 years). Most first-line regimens were platinum-based and the median administered course was 3 (range, 2-7). All patients had responded to the first-line chemotherapy and had performance status (PS) 1 at relapse. The median interval from the end of first-line chemotherapy to relapse was 5.0 months (range, 1.6-36.1 months). The overall response rate of RC was 29%. The median survival time from the beginning of RC was 17.0 months and the 1-year survival rate was 60%. RC led to a significantly better overall survival rate than DOC (p=0.0342). RC could be an active second-line regimen in patients with relapsed NSCLC who responded to first-line chemotherapy.
尚无关于非小细胞肺癌（NSCLC）中与一线化疗相同方案的再挑战化疗（RC）的报道。本研究旨在评估 RC 作为二线化疗在复发性 NSCLC 患者中的疗效。我们回顾性分析了 28 例连续接受 RC 治疗的 NSCLC 患者，并将其临床结局与我院 1992 年 7 月至 2003 年 12 月期间连续 38 例接受多西紫杉醇（DOC）治疗的 NSCLC 患者的临床结局进行了比较。RC 组包括 21 名男性和 7 名女性，中位年龄为 62 岁（范围，42-76 岁）。大多数一线方案为铂类药物，中位疗程为 3 个（范围，2-7 个）。所有患者对一线化疗均有反应，且复发时 PS 评分为 1。从一线化疗结束到复发的中位时间为 5.0 个月（范围，1.6-36.1 个月）。RC 的总体缓解率为 29%。从 RC 开始的中位生存时间为 17.0 个月，1 年生存率为 60%。RC 的总生存率明显优于 DOC（p=0.0342）。RC 可能是对一线化疗有反应的复发性 NSCLC 患者的一种有效二线治疗方案。
